James Ketchum, MD
Internal Medicine · Ballwin, MONPI 1386610376
Payments from drug & device makers
Across 246 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$846
- Lilly USA, LLC$660
- Novo Nordisk$506
- AstraZeneca$334
- Boehringer Ingelheim$272
- GSK$254
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $846 |
| Lilly USA, LLC | 37 | $660 |
| Novo Nordisk | 31 | $506 |
| AstraZeneca | 18 | $334 |
| Boehringer Ingelheim | 15 | $272 |
| GSK | 15 | $254 |
| Pfizer | 14 | $218 |
| Amgen | 11 | $193 |
| Exact Sciences | 7 | $140 |
| Abbott | 7 | $126 |
| Astellas Pharma US Inc | 5 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Optinose US, Inc. | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Johnson & Johnson | 4 | $54 |
| Tris Pharma Inc | 3 | $53 |
| Bayer | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $46 |
| Merck | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Novartis | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,498 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $134,838 |
| MounjaroTirzepatide | 113 | $130,741 |
| JardianceEmpagliflozin | 133 | $129,744 |
| FarxigaDapagliflozin Propanediol | 88 | $89,982 |
| XareltoRivaroxaban | 93 | $77,657 |
| OzempicSemaglutide | 44 | $70,615 |
| TrulicityDulaglutide | 52 | $69,096 |
| JanuviaSitagliptin Phosphate | 49 | $39,645 |
| TradjentaLinagliptin | 45 | $39,066 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 101 | $24,955 |
| WegovySemaglutide | 18 | $23,928 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $21,088 |
| Repatha SureclickEvolocumab | 31 | $16,743 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,693 |
| LinzessLinaclotide | 18 | $12,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $660 | $199,837165 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $272 | $174,106189 claims |
| PfizerEliquis | $218 | $134,838120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $334 | $110,588130 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $506 | $105,90973 claims |
| Johnson & JohnsonXarelto | $54 | $77,65793 claims |
| GSKArexvy, Trelegy Ellipta, Breo Ellipta | $254 | $52,600131 claims |
| MerckJanuvia, Dulera | $46 | $43,32761 claims |
| AbbVieLinzess, Synthroid | $846 | $15,86862 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $11,36218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Ballwin
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.